EUVIMEDEUVIMED entdecken
Crossref

Baseline serum double-mite (D1+D2) sIgE/tIgE ratio as a predictor of early-phase response to dual-mite subcutaneous immunotherapy in allergic rhinitis

Chengzhi Huang, Zhiyuan Tang

Allergologia et Immunopathologia · 01.03.2026 · 54 (2) · 164-169

DOI: 10.15586/aei.v54i2.1514 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergologia et Immunopathologia, online erschienen am 01.03.2026. Verfasst von Chengzhi Huang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology - Head and Neck Surgery, Shenzhen University General Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Immunoglobulin E, Rhinitis, Allergic, Desensitization, Immunologic, Antigens, Dermatophagoides. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Gefördert von: This study was funded by Shenzhen Science and Technology Program No.: JCYJ20200109114244249..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Subcutaneous immunotherapy (SCIT) for allergic rhinitis (AR) requires long-term treatment, and its phased efficacy often influences patient adherence. Identifying early biomarkers, such as serum-specific IgE to total IgE (sIgE/tIgE) ratio, may support individualized management.

Objective

To determine the predictive value of baseline double-mite (D1+D2) sIgE/tIgE ratio for phased dual-mite SCIT response in AR patients.

Methods

We prospectively enrolled 194 AR patients sensitized to Dermatophagoides pteronyssinus (D1) and Dermatophagoides farinae (D2) who received dual-mite SCIT between September 2022 and January 2023. Baseline serum tIgE and sIgE (D1+D2) were measured, and the combined sIgE/tIgE ratio was calculated. Treatment response was evaluated by reduction in visual analogue scale (VAS) scores at months 6 and 12, with the efficacy distribution compared between the two time points using the Chi-square test. Univariable and multivariable logistic regression identified predictors of achieving at least an effective response, and receiver operating characteristic (ROC) analysis was applied for sIgE/tIgE ratio when indicated.

Results

SCIT efficacy improved over time, with a significant shift in response distribution between 6 and 12 months (χ² = 10.084, P = 0.006). At 6 months, multivariable analysis showed that both higher baseline VAS score (OR = 0.954, 95% CI: 0.929–0.980, P < 0.001) and higher sIgE/tIgE ratio (OR = 0.985, 95% CI: 0.972–0.999, P = 0.036) were independently associated with lower likelihood of achieving at least effective response. ROC analysis indicated a cutoff sIgE/tIgE ratio of 26.62% for predicting poor short-term response. At month 12, only baseline VAS score remained a significant predictor (OR = 1.038, 95% CI: 1.005–1.072, P = 0.025).

Conclusion

SCIT efficacy progressively improves over the first year. A higher baseline sIgE (D1+D2)/tIgE ratio (>26.62%) predicts poorer short-term response, highlighting the value of objective biomarkers for early response assessment and individualized management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin ERhinitis, AllergicDesensitization, ImmunologicAntigens, DermatophagoidesHumansFemaleMaleAnimalsProspective StudiesAdultBiomarkersDermatophagoides pteronyssinusTreatment OutcomeDermatophagoides farinaeInjections, SubcutaneousROC CurveYoung AdultDust Mite AllergyAdolescentPredictive Value of TestsMiddle Aged

Stichwörter der Autor:innen

allergen immunotherapypredictive biomarkerspecific IgEtotal IgEtreatment outcome

Substanzen

Immunoglobulin EAntigens, DermatophagoidesBiomarkers

Autor:innen und Institutionen

  • Department of Otorhinolaryngology - Head and Neck Surgery, Shenzhen University General Hospital, Shenzhen, China.
  • Department of Otorhinolaryngology - Head and Neck Surgery, Shenzhen University General Hospital, Shenzhen, China; lancelot32@163.com.

Förderung

  • This study was funded by Shenzhen Science and Technology Program No.: JCYJ20200109114244249.

Zitieren

APA

Huang, C., & Tang, Z. (2026). Baseline serum double-mite (D1+D2) sIgE/tIgE ratio as a predictor of early-phase response to dual-mite subcutaneous immunotherapy in allergic rhinitis. Allergologia et Immunopathologia, 54(2), 164-169. https://doi.org/10.15586/aei.v54i2.1514

Vancouver

Huang C, Tang Z. Baseline serum double-mite (D1+D2) sIgE/tIgE ratio as a predictor of early-phase response to dual-mite subcutaneous immunotherapy in allergic rhinitis. Allergologia et Immunopathologia. 2026;54(2):164-169. doi:10.15586/aei.v54i2.1514

BibTeX
@article{Huang2026,
  author = {Huang, Chengzhi and Tang, Zhiyuan},
  title = {Baseline serum double-mite (D1+D2) sIgE/tIgE ratio as a predictor of early-phase response to dual-mite subcutaneous immunotherapy in allergic rhinitis},
  journal = {Allergologia et Immunopathologia},
  year = {2026},
  volume = {54},
  number = {2},
  pages = {164--169},
  doi = {10.15586/aei.v54i2.1514}
}
Kostenlos starten →